Mainowei Pharmaceutical Technology

About Mainowei Pharmaceutical Technology

Nanjing Mainowei Pharmaceutical Technology Co., Ltd. (Minova Pharma) is a pharmaceutical research and development company established in February 2021 and headquartered in Nanjing, China. The company focuses on developing a portfolio of products for mental and disfiguring diseases, positioning itself as a supplier in the consumer pharmaceutical sector. The core technical strategy involves integrating molecular structure innovation with novel drug delivery systems to create new drugs with superior clinical efficacy, better safety, and an improved patient experience.

The company was founded by Dr. Liu Fei, who serves as the General Manager and has over 15 years of experience in new drug R&D and management. The founding team also includes Dr. Lu Guangwei as Chief Technical Advisor, Dr. Tang Shuai as Deputy General Manager, and Ms. Zhang Cuixia as Deputy General Manager. This core team has a history of collaboration exceeding a decade, having previously led the research, development, and regulatory submissions for numerous new drugs in both China and the United States.

Minova Pharma has established two main product pipelines: "Mental Beauty" for psychiatric conditions and "Image Beauty" for disfiguring diseases like hair loss, acne, and photoaging. Its research and development efforts are supported by several platforms, including a phenotype-based drug screening platform for disfiguring diseases, a technology platform for the total synthesis of complex natural small molecules, and various novel drug delivery system platforms for complex injectables, topicals, and oral formulations. As of August 2025, the company had recently secured a Series B financing round of several hundred million yuan, led by IDG Capital with participation from Yuanhe Origin, to advance its research pipeline.